| Oh SY, Ju YT, Choi SK, et al.
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 19.
Abstract | Full Citation | | Takahashi Y, Hazawa M, Takahashi K, et al.
Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 17.
Abstract | Full Citation | Find Related Articles | | Benites J, Valderrama JA, Taper H, et al.
An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 17.
Abstract | Full Citation | | Hutchens S, Manevich Y, He L, et al.
Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 16.
Abstract | Full Citation | | O'Donovan N, Byrne AT, O'Connor AE, et al.
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 16.
Abstract | Full Citation | Find Related Articles | | Momekov G, Karaivanova M, Ugrinova I, et al.
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 13.
Abstract | Full Citation | Find Related Articles | | Viéitez JM, Valladares M, Peláez I, et al.
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 6.
Abstract | Full Citation | | Xu XF, Cai BL, Guan SM, et al.
Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 6.
Abstract | Full Citation | | Fu JN, Li J, Tan Q, et al.
Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. [JOURNAL ARTICLE]
Invest New Drugs 2010 Mar 2.
Abstract | Full Citation | Find Related Articles | | Sridhar SS, Winquist E, Eisen A, et al.
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. [JOURNAL ARTICLE]
Invest New Drugs 2010 Feb 27.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
|
